Breaking News

Aesica Adds Commercial Director Position

By Kristin Brooks | February 3, 2014

Muir to lead all three of the company’s service offerings

Ian Muir has been appointed to the newly created position of commercial managing director at Aesica, effective February 24th. Mr. Muir will be responsible for all three of the company’s service offerings in API manufacture, formulation development and formulated products, and will lead business expansion efforts into new growth markets including China and Japan. He will report to chief executive officer, Dr. Robert Hardy.
 
Aesica’s business development, sales and marketing, key account and product management teams will report to Mr. Muir, who will be based at the company’s headquarters in Newcastle, UK.
 
Mr. Muir has 20 years of experience in the pharma industry. Most recently he was responsible for the global provision of contract development and manufacturing services for oral dose forms at Catalent. He has gained significant commercial experience in contract manufacturing roles for large pharmaceutical companies in Europe, the U.S. and Australia, and has led R&D activities and commercial manufacturing operations.
 
Dr. Hardy said, “Ian brings strong commercial business knowledge and has proven experience of delivering growth and will play a pivotal role in driving further business growth for Aesica across API, formulation development and formulated products.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important